Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

Helene Mens; Lasse Fjordside; Jannik Fonager; Jan Gerstoft

doi:10.3390/idr14040053

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

Infect Dis Rep. 2022 Jun 22;14(4):501-504. doi: 10.3390/idr14040053.

Authors

Helene Mens¹, Lasse Fjordside¹, Jannik Fonager², Jan Gerstoft¹

Affiliations

¹ Rigshospitalet, Department of Infectious Diseases, 2100 Copenhagen, Denmark.
² Viruses and Microbial Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.

Abstract

HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

Keywords: HIV-1; drug resistance; integrase inhibitors.

Grants and funding

This research received no external funding.